Sentinel node biopsy in Low- and Intermediae endometrial cancer Management: The SLIM-study

Sentinel node biopsy in Low- and Intermediae endometrial cancer Management: The SLIM-study - SLIM study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON41827

Enrollment

142

Registered

2016-02-17

Start date

2016-05-30

Completion date

Unknown

Last updated

2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer of the uterus endometrial cancer

Interventions

Patients with a positive sentinel node will be upgrade towards a stage 3A diases and treated accordingly with adjuvant external beam radiotherapy.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: low-risk endometrial cancer: type 1 endometrial cancer, stage 1A grade 1 or 2 Intermediate-risk endometrial cancer: type 1 endometrial cancer, stage 1B grade 1 or 2

Exclusion criteria

Exclusion criteria: - high-risk endometrial cancer: type 2 endometrial cancer, endometrial cancer, 2 or higher or endometrial cancer type 1 stage 1B grade 2 or 3 - intermediate-risk endometrial cancer stage 1A grade 3 - women unfit for surgery - women unfit for scintigram

Design outcomes

Primary

Measure	Time frame
- the presence of micro- and macro metastasis - to examine in how many cases SLN biopsy provides results that change adjuvant treatment	—

Secondary

Measure	Time frame
- disease free survival data - Quality of Life data	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Feb 19, 2026